Will novel oral formulations change the management of inflammatory bowel disease?

Expert Opinion on Investigational Drugs

Volumn 25, Issue 6, 2016, Pages 709-718

  Nielsen, Ole Haagen ^a   Seidelin, Jakob Benedict ^a   Ainsworth, Mark ^a   Coskun, Mehmet ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti sense therapy; Crohn s disease; inflammatory bowel disease; oral therapy; small molecules; ulcerative colitis

Indexed keywords

AJM 300; SMAD7 PROTEIN; ANTISENSE OLIGONUCLEOTIDE; IMMUNOLOGIC FACTOR;

ANTISENSE THERAPY; DRUG FORMULATION; DRUG TARGETING; FIBROSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; MULTICENTER STUDY (TOPIC); NONHUMAN; OLIGONUCLEOTIDE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STENOSIS; ANIMAL; DRUG DESIGN; INFLAMMATORY BOWEL DISEASES; MOLECULARLY TARGETED THERAPY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE;

EID: 84961666319     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1165204     Document Type: Review

References (85)

1. R.Atreya, M.F.Neurath IBD pathogenesis in 2014: molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol. 2015;12(2):67–68.
2. O.H.Nielsen, L.K.Munck. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4(3):160–170.
3. A.C.Ford, C.N.Bernstein, K.J.Khan, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–599.
4. M.Coskun, C.Steenholdt, N.K.de Boer, et al. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin Pharmacokinet. 2016;55(3):257–274.
5. O.H.Nielsen, M.A.Ainsworth. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369(8):754–762.
6. A.K.Chandar, S.Singh, M.H.Murad, et al. Efficacy and safety of natalizumab and vedolizumab for the management of Crohn’s disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(7):1695–1708.
7. B.G.Feagan, P.Rutgeerts, B.E.Sands, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
8. S.Danese, L.Vuitton, L.Peyrin-Biroulet. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537–545.
9. C.M.Olesen, M.Coskun, L.Peyrin-Biroulet, et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110–119.
10. S.Vermeire, S.Ghosh, J.Panes, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60(8):1068–1075.
11. S.Vermeire, S.O’Byrne, M.Keir, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–318.
12. E.Shelton, J.R.Allegretti, B.Stevens, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879–2885.
13. A.Amiot, J.-C.Grimaud, X.Treton, et al. The French real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicenter cohort study. In. United European Gastroenterology Week. OP049, Vienna. October15–19, 2015.
14. A.Amiot, L.Peyrin-Biroulet, C.Stefanescu, et al. Management of IBD after anti-TNF failure. In: United European Gastroenterology Week, OP054, Vienna, October15–19, 2015
15. D.Baumgart, R.Atreya, O.Bachmann, et al. Vedolizumab for inflammatory bowel disease in clinical practice - experience from a prospective German registry. In: United European Gastroenterology Week, OP053, Vienna, October15–19, 2015
16. G.Bloomgren, S.Richman, C.Hotermans, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
17. S.Mozaffari, S.Nikfar, M.Abdollahi. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs. 2015;24(7):949–956.
18. K.Ghoreschi, A.Laurence, J.J.O’Shea. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287.
19. M.Coskun, M.Salem, J.Pedersen, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76(10):1–8.
20. W.J.Sandborn, S.Ghosh, J.Panes, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624.• First study to show clinical efficacy of JAK1 and −3 inhibitor for treatment of ulcerative colitis.
21. K.Ghoreschi, M.I.Jesson, X.Li, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243.
22. R.J.Riese, S.Krishnaswami, J.Kremer. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513–526.
23. W.J.Sandborn, S.Ghosh, J.Panes, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485–1493.
24. B.S.Boland, W.J.Sandborn, J.T.Chang. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):603–617.
25. A Study Evaluating the Efficacy and Safety of CP-690,550 in Patients with Moderate to Severe Ulcerative Colitis [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01465763.
26. A Study to Evaluate Both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis (OCTAVE) [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01458951.
27. A Study of Oral CP-690,550 as a Maintenance Therapy for Ulcerative Colitis (OCTAVE) [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01458574.
28. Long-Term Study of CP-690,550 in Subjects with Ulcerative Colitis (OCTAVE) [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01470612.
29. J.Panes, C.Su, A.G.Bushmakin, et al. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol. 2015;15:14.
30. R.N.Maini, P.C.Taylor, J.Szechinski, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–2829.
31. L.Peyrin-Biroulet, S.Danese. Tofacitinib: janus bifrons in ulcerative colitis treatment. Gastroenterology. 2013;144(5):1136–1138.
32. F.Namour, P.M.Diderichsen, E.Cox, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–874.
33. Efficacy and Safety of GLPG0634 in Subjects with Active Crohn’s Disease [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02048618.
34. A Study of Safety and Effectiveness of JNJ-54781532 in Patients with Moderately to Severely Active Ulcerative Colitis [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01959282.
35. C.Wegner, C.Stadelmann, R.Pfortner, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227(1–2):133–143.
36. J.S.Yang, L.Y.Xu, B.G.Xiao, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004;156(1–2):3–9.
37. M.Varrin-Doyer, S.S.Zamvil, U.Schulze-Topphoff. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014;262:A66–71.
38. G.D’Haens, W.J.Sandborn, J.F.Colombel, et al. A phase II study of laquinimod in Crohn’s disease. Gut. 2015;64(8):1227–1235.• Interesting study of a new oral agent with an unknown target in the inflammatory process indicating efficacy in Crohn’s disease
39. T.Sugiura, S.Kageyama, A.Andou, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013;7(11):e533–e542.
40. N.Yoshimura, M.Watanabe, S.Motoya, et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149(7):1775–1783.• This new α4 antagonist with clinical efficacy in ulcerative colitis may share mechanism of action with natalizumab with respect to JC virus activation. Morte long-term safety studies are needed.
41. U.H.Von Andrian, B.Engelhardt. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348(1):68–72.
42. H.Rosen, P.J.Gonzalez-Cabrera, M.G.Sanna, et al. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem. 2009;78:743–768.
43. T.Sanchez, T.Hla. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004;92(5):913–922.
44. E.Degagne, J.D.Saba. S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin Exp Gastroenterol. 2014;7:205–214.
45. W.J.Sandborn, B.G.Feagan, D.C.Wolf, et al. The Touchstone study: a randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis. Gastroenterology. 2015;148:S–93.• This is the first reported efficacy of an agonist for sphingosine-1-phosphate receptors in ulcerative colitis.
46. Open-label extension of RPC1063 as therapy for moderate to severe ulcerative colitis [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02531126?term=RPC1063&rank=7.
47. Safety and efficacy trial of RPC1063 for moderate to severe ulcerative colitis [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02435992?term=RPC1063&rank=5.
48. Efficacy and safety trial of RCP1063 for moderate to severe Crohn’s disease [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02531113?term=RPC1063&rank=6.
49. Safety and efficacy of APD334 in patients with ulcerative colitis [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02447302?term=APD334&rank=1.
50. Safety and efficacy of MT-1303 in subjects with moderate to severe active Crohn’s disease [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02378688?term=MT-1303&rank=10.
51. Extension study of MT-1303 in subjects with Crohn’s disease [cited 2016 March1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02389790?term=MT-1303&rank=11
52. L.Gorelik, R.A.Flavell. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002;2(1):46–53.
53. J.J.Letterio, A.B.Roberts. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137–161.
54. C.H.Heldin, K.Miyazono. P.Ten Dijke TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390(6659):465–471.
55. A.B.Kulkarni, S.Karlsson. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol. 1993;143(1):3–9.
56. M.F.Neurath, I.Fuss, B.L.Kelsall, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med. 1996;183(6):2605–2616.
57. F.Powrie, J.Carlino, M.W.Leach, et al. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996;183(6):2669–2674.
58. G.Monteleone, R.Caruso, F.Pallone. Role of Smad7 in inflammatory bowel diseases. World J Gastroenterol. 2012;18(40):5664–5668.
59. G.Monteleone, A.Kumberova, N.M.Croft, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108(4):601–609.
60. I.Marafini, F.Zorzi, S.Codazza, et al. TGF-Beta signaling manipulation as potential therapy for IBD. Curr Drug Targets. 2013;14(12):1400–1404.
61. G.Monteleone, M.C.Fantini, S.Onali, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther. 2012;20(4):870–876.
62. M.Boirivant, F.Pallone, G.C.Di, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006;131(6):1786–1798.
63. G.Monteleone, M.F.Neurath, S.Ardizzone, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372(12):1104–1113.• A randomized controlled trial for two weeks treatment with a SMAD7 anti-sense oligonucleotide in Crohn’s disease.
64. Efficacy and safety study of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease [cited 2016 March1]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02596893?term=NCT02596893&rank=1
65. An efficacy and safety study of mongersen (GED-0301) in subjects with active ulcerative colitis [cited 2016 March1]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02601300?term=NCT02601300&rank=1.
66. J.P.Burke, J.J.Mulsow, C.O’Keane, et al. Fibrogenesis in Crohn’s disease. Am J Gastroenterol. 2007;102(2):439–448.
67. I.C.Lawrance, L.Maxwell, W.Doe. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7(1):16–26.
68. A.Nijhuis, P.Biancheri, A.Lewis, et al. In Crohn’s disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci (Lond). 2014;127(5):341–350.
69. J.J.Mulsow, R.W.Watson, J.M.Fitzpatrick, et al. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg. 2005;242(6):880–889.
70. M.C.Regan, B.M.Flavin, J.M.Fitzpatrick, et al. Stricture formation in Crohn’s disease: the role of intestinal fibroblasts. Ann Surg. 2000;231(1):46–50.
71. C.Li, R.S.Flynn, J.R.Grider, et al. Increased activation of latent TGF-beta1 by alphaVbeta3 in human Crohn’s disease and fibrosis in TNBS colitis can be prevented by cilengitide. Inflamm Bowel Dis. 2013;19(13):2829–2839.
72. C.Li, A.Iness, J.Yoon, et al. Noncanonical STAT3 activation regulates excess TGF-beta1 and collagen I expression in muscle of stricturing Crohn’s disease. J Immunol. 2015;194(7):3422–3431.
73. L.A.Feagins. Role of transforming growth factor-beta in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis. 2010;16(11):1963–1968.
74. S.Fichtner-Feigl, W.Strober, K.Kawakami, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99–106.
75. C.Medina, M.J.Santos-Martinez, A.Santana, et al. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol. 2011;224(4):461–472.• This paper points to the risk for side effects of SMAD7 anti-sense therapy with respect to development of intestinal fibrosis and thereby stenosis and risk for surgery when used as long-term (i.e. maintenance) therapy.
76. B.A.Karimi-Shah, B.A.Chowdhury. Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372(13):1189–1191.
77. T.E.KingJr., W.Z.Bradford, S.Castro-Bernardini, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
78. M.Scharl, S.Frei, T.Pesch, et al. Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut. 2013;62(1):63–72.
79. F.Bataille, C.Rohrmeier, R.Bates, et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn’s disease. Inflamm Bowel Dis. 2008;14(11):1514–1527.
80. S.M.Frei, C.Hemsley, T.Pesch, et al. The role for dickkopf-homolog-1 in the pathogenesis of Crohn’s disease-associated fistulae. PLoS One. 2013;8(11):e78882.
81. R.C.Bates, D.I.Bellovin, C.Brown, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115(2):339–347.
82. S.Uttamsingh, X.Bao, K.T.Nguyen, et al. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene. 2008;27(18):2626–2634.
83. R.C.Bates, A.M.Mercurio. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell. 2003;14(5):1790–1800.
84. M.Bewtra, A.O.Fairchild, E.Gilroy, et al. Inflammatory bowel disease patients’ willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol. 2015;110(12):1675–1681.
85. D.Tracey, L.Klareskog, E.H.Sasso, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.